An article by our Chief Scientific Officer Mick Foley reviewing the emergence of next-generation antibody like therapeutics including I-bodies was published in the latest issue of European Biopharmaceutical Review (EBR).
To read the article, click here.
For the contents of the current issue of EBR, click here.
Disclaimer:
This article is taken from European Biopharmaceutical Review April 2020, pages 32-35. © Samedan Ltd